Soluble Suppression of Tumorigenicity-2 Levels As Prognostic Marker in Non-ST-segment Elevation Myocardial Infarction

Sherly Purnamawaty, Tenri Esa, Ibrahim Abd Samad


Acute Myocardial Infarction (IMA) is the most severe manifestation of coronary arterial disease, and about 60%-75% of
IMA is NSTEMI. It is known that complications are associated with high mortality rates; therefore, predicting the
development of complications in NSTEMI will help physicians improve risk stratification and determine optimal treatment.
Suppression of tumorigenicity-2 (ST2) is a family of interleukin-1 (IL-1) receptors. Ischemia, injury, and myocardial infarction
will cause cardiomyocytes to release sST2 associated with a worse prognosis. This study aimed to analyze sST2 levels in
NSTEMI patients as a prognostic marker. This study used a prospective cohort method performed on NSTEMI patients
treated at Pusat Jantung Terpadu of Dr. Wahidin Sudirohusodo Hospital during March 2019. Forty-two patients were
involved as samples. All patients were tested for sST2 levels by immunochromatography and followed up during
hospitalization. Data on the development of heart failure, arrhythmia, cardiogenic shock, sudden cardiac arrest, length of
stay, and outcome were recorded during follow-up. Data were statistically analyzed with Mann-Whitney and Spearman test.
The results of the sST2 level in NSTEMI with and without heart failure were 114.09±92.01 ng/mL and 58.94±57.75 ng/mL
(p=0.014), respectively. There was no significant difference between sST2 levels in NSTEMI with complications of
arrhythmias, cardiogenic shock, and sudden cardiac arrest compared and patients without those complications (p>0.05).
The level of sST2 was significantly higher in NSTEMI patients who passed away (164.05±77.35 ng/mL) than those who
survived (72.55±73.15 (p=0.027). There was no correlation between sST2 levels and length of stay (p=0.947). It was
concluded that sST2 levels could be a prognostic marker for NSTEMI, particularly heart failure and outcome.


NSTEMI, sST2 heart failure, arrhythmia, cardiogenic shock, sudden cardiac arrest, mortality

Full Text:



Reed GW, Rossi JE, Cannon CP. Acute myocardial infarction. The Lancet. 2017; 389(10065): 197-210.

World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization. Global Atlas on Cardiovascular Disease Prevention and Control. 2011; 8-13.

Mullasari AS, Balaji P, Khando T. Managing complications in acute myocardial infarction. J Assoc Physicians India. 2011; 59:43-8.

Bajaj A, Sethi A, Rathor P, Suppogu N, Sethi A. Acute complications of myocardial infarction in the current era: diagnosis and management. Journal of investigative medicine. 2015; 63(7):844-855.

Bahit MC, Lopes RD, Clare RM, Newby LK, Pieper KS, Van de Werf F, et al. Heart failure complicating non–ST-segment elevation acute coronary syndrome: timing, predictors, and clinical outcomes. JACC: Heart Failure. 2013; 1(3): 223-229.

Roubín S, Abu-Assi E, López-López A, Bouzas-Cruz N, Castiñeira-Busto M, Cambeiro-González, et al. Risk stratification for the development of heart failure after acute coronary syndrome at the time of hospital discharge: predictive ability of GRACE risk score. Journal of cardiology. 2015; 66(3): 224-231.

Salvagno GL and Pavan C. Prognostic biomarkers in acute coronary syndrome. Annals of translational medicine. 2016; 4(13): 1-8.

Demyanets S, Speid WS, Tentzeris I, Jarai R, Katsaros KM, Farhan S. Soluble ST2 and interleukin-33 levels in coronary artery disease: relation to disease activity and adverse outcome. PLoS One. 2014; 9(4): e95055.

Konukoglu D. Is soluble ST2 a new marker in heart failure?. International Journal of Medical Biochemistry. 2018; 1(1): 44-51.

Genis A, de Antonio M, Vila J, Peñafiel J, Galán A, Barallat J, et al. Head-to-head comparison of 2 myocardial fibrosis biomarkers for long-term heart failure risk stratification: ST2 versus galectin-3. Journal of the American College of Cardiology. 2014; 63(2):158-166.

Richards AM, Di Somma S, Mueller T. ST2 in stable and unstable ischemic heart diseases. The American journal of cardiology. 2015; 115(7): 48B-58B.

Eggers KM, Armstrong PW, Califf RM, Simoons ML, Venge P, Wallentin L, James SK. ST2 and mortality in non–ST-segment elevation acute coronary syndrome. American heart journal. 2010; 159(5): 788-794.

Barbarash O, Gruzdeva O, Uchasova E, Dyleva Y, Belik E, Akbasheva O, et al. Prognostic value of soluble ST2 during hospitalization for ST-segment elevation myocardial infarction. Annals of laboratory medicine. 2016; 36(4): 313-319.

Aldous SJ, Richards AM, Troughton R, Than M. ST2 has diagnostic and prognostic utility for all-cause mortality and heart failure in patients presenting to the emergency department with chest pain. Journal of cardiac failure. 2012; 18(4): 304-310.

Gomar F, Perez-Quilis C, Leischik R, Lucia A. Epidemiology of coronary heart disease and acute coronary syndrome. Annals of translational medicine. 2016; 4(13).

Kytö V, Sipilä J, Rautava P. Association of age and gender with risk for non-ST-elevation myocardial infarction. European journal of preventive cardiology. 2015; 22(8): 1003-1008.

Hamm CW, Heeschen C, Falk E, Fox KA. Acute Coronary Syndromes: Pathophysiology, Diagnosis and Risk Stratification. 2014

Lapu-Bula R, Onwuanyi A, Bielo MV, Deffer O, Quarshi A, Alema-Mensah E, et al. Risk factors for acute non-ST-segment elevation myocardial infarction in a population sample of predominantly African American patients with chest pain and normal coronary arteries. Ethnicity & disease. 2011; 21(4): 421.

Hubacek JA, Stanek V, Gebauerova M, Adamkova V, Lesauskaite V,

Zaliaduonyte-Peksiene D, et al. Traditional risk factors of acute coronary syndrome in four different male populations–total cholesterol value does not seem to be relevant risk factor. Physiol Res. 2017; 66(1): S121-S128.

Kohli P, Bonaca MP, Kakkar R, Kudinova AY, Scirica BM, Sabatine MS, et al. Role of ST2 in non ST-elevation acute coronary syndrome in the MERLIN-TIMI 36 trial. Clin Chem. 2012; 58:257e266.

Bhardwaj A and Januzzi JL. ST2: a novel biomarker for heart failure. Expert review of molecular diagnostics. 2010; 10(4): 459-464.

Hashimoto T and Kass DA. Stressed hearts inflame the body (in a good way). Proceedings of the National Academy of Sciences. 2015; 112(23): 7113-7114.

Ciccone MM, Cortese F, Gesuald M, Riccardi R, Di Nunzio D, Moncelli M, et al. A novel cardiac bio-marker: ST2: a review. Molecules. 2013; 18(12): 15314-15328.

Chen LQ, de Lemos JA, Das SR, Ayers CR, Rohatgi A. Soluble ST2 is associated with all-cause and cardiovascular mortality in a population-based cohort: the Dallas Heart Study. Clinical Chemistry. 2013; 59(3): 536-546.



  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.